Typically, $100,000 to $150,000 per quality-adjusted life-year is accepted as cost-effective, but Avastin as a first-line treatment was associated with a $240,814 price tag per QALY. As a second-line treatment, Avastin cost $363,066 per QALY.
The drug may become cost-effective if a biomarker to identify the patients who would most benefit was discovered. Researchers have yet to identify such a biomarker.
More articles on gastroenterology:
Balloon colonoscope improves polyp detection
10 statistics on gastroenterologist salary by subspecialty
Gastroenterologists & ACOs: In or out?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
